RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Phase 1/2 Completed
29 enrolled
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Phase 2 Terminated
55 enrolled
AML1208
Phase 1 Completed
11 enrolled
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 2 Completed
277 enrolled 11 charts
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 1/2 Completed
24 enrolled 9 charts
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 1 Unknown
21 enrolled
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
Phase 1/2 Completed